EBV-positive lymphoproliferations of B- T- and NK-cell derivation in non-immunocompromised hosts[J]. Pathogens, 2018, 7(1):28-30. [2] ndrei G, Trompet E, Snoeck R. Novel therapeutics for Epstein?Barr virus[J]. Molecules, 2019, 24(5):E997-E999. [3] matti MK, Al-Sadeq DW, ...
It is well understood that EBV can cause a variety of cancers in some patients, particularly immunocompromised hosts, including nasopharyngeal carcinoma, Burkitt lymphoma, Hodgkin's and non- Hodgkin's lymphomas, gastric carcinoma, ...
Epstein Barr virus-positive mucocutaneous ulceration (EBVMCU) is an uncommon entity first described in 2010. This lymphoproliferative disorder was first described in immunocompromised patients presenting with well-defined ulceration involving the oral cavity, skin and gastrointestinal tract. The first ...
2B; EBER-1, -2 and BART) Latency I: express EBNA-1 (BL, EBV+ gastric carcinoma) Latancy II: express EBNA-1, LMP1, LMP2 (HL, NPC) Latency III: express all genes (PTLD, AIDS-related lymphomas) EBV-associated lymphoproliferative diseases in non-immunocompromised hosts Cohen JI , et al...
The Epstein-Barr virus (EBV) is a ubiquitous virus that causes infectious mononucleosis in people with normal immune function; however, in immunocompromised patients such as those undergoing hematopoietic cell or solid organ transplants, it can cause lymphoma and other cancers. EBV-CTLs are a ...
Cohen JI, Kimura H, Nakamura S, Ko YH, Jaffe ES . Epstein-Barr virus-associated lymphoproliferative disease in non-immunocompromised hosts: a status report and summary of an international meeting, 8–9 September 2008.Ann Oncol2009;20: 1472–1482. ...
4.2 EBNA2 EBNA2, a 487 aa protein, is expressed in vivo during latency III shortly after infection of B cells or in lymphomas occurring in immunocompromised patients and in LCL. As mentioned above, the variations in EBNA2 make it possible to classify EBV as types 1 and 2 (or A and B...
cells.However,inthecaseofEBV,thesecellsareprimaryBlymphocytes,whichEBVlatentlyinfects withveryhighefficiency,bothinvivoandinvitro.Thetriggersthesecellstostarttoproliferate, andthensustainstheirproliferationthroughtheexpressionofspecificgrowth-promotinggeneswhich ...
In immunocompromised patients, Epstein-Barr virus (EBV) infection or reactivation is associated with increased morbidity and mortality, including the development of B-cell lymphomas. The first-line treatment consists of reduction of immunosuppression and administration of rituximab (anti-CD20 antibody). Fu...
In agreement with this speculation, reactivation of latent EBV infection was considered an important pathogenic mechanism of EBV-related diseases in immunocompromised patients such as those with PTLD or HIV [48, 49]. However, patients with other solid tumors didn't show higher EBV activities than ...